| 2011 |
HHARI (ARIH1) functions as a RING/HECT hybrid E3 ligase: it binds E2 (UBCH7) via its RING1 domain but transfers ubiquitin through an obligate thioester intermediate at a conserved cysteine in the RING2 domain, classifying RBR ligases as mechanistically distinct from canonical RING E3s. |
In vitro ubiquitin transfer assays, active-site cysteine mutagenesis, biochemical characterization of E2-E3 pairs |
Nature |
High |
21532592
|
| 1999 |
HHARI (ARIH1) interacts specifically with UbcH7 and UbcH8 (but not UbcH5 or UbcH1) via its N-terminal RING1 finger motif and IBR domain, identified by yeast two-hybrid screen and confirmed by in vitro binding studies. |
Yeast two-hybrid screen, in vitro binding assays (pulldown) |
The Journal of biological chemistry |
Medium |
10521492
|
| 2001 |
HHARI (ARIH1) co-localizes with UbcH7 in the perinuclear region of mammalian cells; a minimal interaction region (residues 186–254) was defined, specific amino acid residues essential for the RING1–UbcH7 interaction were identified, and conversion of RING1 from RING-HC to RING-H2 type abolishes interaction. |
Co-immunoprecipitation in mammalian cells, co-localization by immunofluorescence, deletion/point mutagenesis |
The Journal of biological chemistry |
Medium |
11278816
|
| 2013 |
HHARI (ARIH1) and TRIAD1, Ariadne-subfamily RBR ligases, associate with distinct neddylated Cullin-RING ligase (CRL) complexes; neddylated CRL binding greatly stimulates HHARI RBR ligase activity in vitro (auto-ubiquitylation, thioester discharge, ubiquitin-vinyl methyl ester reactivity), and RBR ligase activity reciprocally impacts CRL levels and activities in vivo. |
Co-immunoprecipitation, in vitro ubiquitylation assays, ubiquitin-vinyl methyl ester reactivity, genetic (in vivo) CRL activity assays |
The EMBO journal |
High |
24076655
|
| 2013 |
The NMR solution structure of the HHARI RING2 domain was determined, revealing two Zn2+-binding sites, a single exposed catalytic cysteine, and a near-mirror-image arrangement of catalytic residues compared to HECT E3 ligase NEDD4, providing structural rationale for the RING/HECT hybrid mechanism. |
NMR structure determination, structural comparison with HECT E3 ligases |
PloS one |
High |
24058416
|
| 2015 |
ARIH1 protects cells against genotoxic stress by promoting non-degradative ubiquitination of 4EHP (a competitive eIF4E inhibitor), localizing to perinuclear ribosome-containing regions after DNA damage, and inducing mRNA translation arrest in an ARIH1 ubiquitin-ligase-activity-dependent manner; ATM signaling stabilizes ARIH1 protein by attenuating its proteasomal degradation. |
RNAi screen, expression of wild-type vs. ubiquitinase-defective ARIH1 mutants, subcellular fractionation, co-immunoprecipitation (ARIH1–4EHP), mRNA translation assays, cell viability assays |
Molecular and cellular biology |
Medium |
25624349
|
| 2017 |
Crystal/structural studies showed that HHARI RING1 contains a unique Zn2+-loop II extension (not present in canonical RING E3s) that acts as a steric wedge to enforce an open E2~Ub conformation, explaining how RBR RING1 promotes Ub transfer to the E3 active-site cysteine rather than directly to substrate. |
X-ray crystallography of HHARI/UbcH7~Ub complex, mutagenesis, biochemical validation |
Structure |
High |
28552575
|
| 2018 |
Drosophila Ari-1 (ortholog of ARIH1) mono-ubiquitinates the LINC complex member Koi, regulating myonuclear positioning; Ari-1 and Parkin are functionally redundant for this process (each rescues the other's mutant phenotype); human ARIH1 rescues fly ari-1 mutants whereas patient-derived ARIH1 variants fail to do so. |
Drosophila genetics (loss-of-function, rescue experiments), in vitro/in vivo ubiquitination assays (mono-ubiquitination of Koi), immunofluorescence of LINC complex members |
Developmental cell |
High |
29689197
|
| 2021 |
ARIH1 is the E3 ubiquitin ligase that ubiquitinates PD-L1 following GSK3α-mediated phosphorylation at Ser279/Ser283, targeting PD-L1 for proteasomal degradation; ARIH1 overexpression suppresses tumor growth and promotes cytotoxic T cell activation in immunocompetent but not immunocompromised mice. |
Co-immunoprecipitation, ubiquitination assays, ARIH1 overexpression/knockdown in tumor models, in vivo syngeneic tumor experiments, high-throughput drug screen |
Nature communications |
Medium |
33879767
|
| 2022 |
ARIH1 catalyzes mono-ISGylation of cGAS at K187, which promotes cGAS oligomerization and activation, thereby enhancing type I interferon and proinflammatory cytokine production in response to HSV-1 or cytoplasmic DNA; conditional Arih1 knockout mice are hypersensitive to HSV-1 and show reduced autoimmune phenotypes in TREX1-deficient background. |
Co-immunoprecipitation, ISGylation assays, ARIH1 KO/KD (siRNA, conditional mouse knockouts), HSV-1 infection models, site-directed mutagenesis (K187) |
Nature communications |
High |
36217001
|
| 2022 |
ARIH1 ubiquitinates hnRNP-E1, promoting its degradation and thereby facilitating EMT induction; ARIH1 silencing increases hnRNP-E1 stability and reduces ubiquitination, delays EMT and invasion, while ARIH1 overexpression promotes EMT and invasion; ARIH1 silencing in breast cancer cells reduces cancer stem cell properties in vitro and tumor formation in vivo. |
Yeast two-hybrid (interaction identification), ARIH1 KD/OE in mammary epithelial and breast cancer cell lines, ubiquitination assays, miniTurboID proximity labeling, in vivo tumor formation assays |
Oncogene |
Medium |
35102251
|
| 2022 |
The HHARI (ARIH1) Rcat (RING2) domain contains a di-aromatic surface that forms a binding platform for substrate recruitment (demonstrated for 4EHP); a phosphomimetic mutation on the auto-inhibitory Ariadne domain promotes Rcat release and reorientation enabling transthiolation and substrate modification, defining a general model for RBR substrate recognition. |
XL-MS, HDX-MS, NMR, biochemical binding and ubiquitination assays, phosphomimetic mutagenesis |
Structure |
High |
35716664
|
| 2023 |
ARIH1 mediates ubiquitination and proteasomal degradation of DNA-PKcs, thereby activating the STING pathway and promoting cytotoxic T cell infiltration; a phospho-mimetic mutant of cGAS (T68E/S213D) blocks this ARIH1-DNA-PKcs-STING signaling axis. |
Co-immunoprecipitation, ubiquitination assays, ARIH1 overexpression/knockdown, syngeneic in vivo tumor models, high-throughput drug screen |
Nature communications |
Medium |
37429863
|
| 2023 |
ARIH1 catalyzes serine (oxyester) ubiquitylation in addition to canonical lysine (isopeptide) ubiquitylation on CRL-bound substrates; efficiency of Ser ubiquitylation is highly dependent on local sequence context; comprehensive mutagenesis of the Rcat domain identified residues differentially affecting oxyester vs. isopeptide bond formation. |
In vitro reconstitution with purified components, comprehensive active-site mutagenesis of Rcat domain, biochemical ubiquitylation assays measuring Ser vs. Lys ubiquitylation |
The Biochemical journal |
High |
37870100
|
| 2023 |
ARIH1 interacts with SQSTM1/p62 and enhances RIG-I stability (via p62-mediated pathway), thereby promoting IFN-β and downstream ISG expression during influenza A virus infection; ARIH1 is upregulated during IAV infection. |
Co-immunoprecipitation, Western blot, TCID50 viral titer assay, luciferase reporter assay, siRNA knockdown |
Virology journal |
Low |
37005687
|
| 2006 |
C. elegans ARI-1 (ARIH1 ortholog) functions as an RBR ubiquitin ligase with UBC-18 (ortholog of UbcH7) to control pharyngeal morphogenesis; genetic interactions show ARI-1 is the principal Ariadne family member for this process, and GFP reporters show dynamic expression in muscles and neurons. |
Yeast two-hybrid (ARI-1/UBC-18 interaction), C. elegans genetic analysis (double mutants, RNAi), GFP reporter expression |
Developmental biology |
Medium |
16457801
|
| 2009 |
In C. elegans, UBC-18 (UbcH7 ortholog)–ARI-1 (ARIH1 ortholog) complex acts in ubiquitin-mediated proteolysis to negatively regulate SUP-35 abundance, functioning redundantly with LIN-35/Rb (which acts as a transcriptional repressor of sup-35) to control pharyngeal morphogenesis; genetic suppressor analysis showed sup-35 mutations revert synthetic lethality of ubc-18; pha-1 double mutants. |
Genetic epistasis analysis, double/triple mutant analysis, molecular analysis of SUP-35 abundance |
PLoS genetics |
Medium |
19521497
|
| 2012 |
HHARI (ARIH1) localizes to both nucleus and cytoplasm, with higher nuclear levels; it co-localizes with Cajal bodies (p80 coilin, NOPP140), PML bodies, and SC35 bodies; ARIH1 knockdown causes reduced proliferation, increased apoptosis, G2 cell cycle arrest, and reduced total cellular RNA levels. |
Antibody-based immunofluorescence, RNAi knockdown screen, flow cytometry (cell cycle analysis), RNA quantification |
Experimental cell research |
Medium |
23059369
|
| 2011 |
HHARI (ARIH1) binds many of the same substrate proteins as parkin (including CDCrel-1, synphilin-1, and CASK) in vitro, forms aggresomes morphologically indistinguishable from parkin-induced aggresomes (microtubule-dependent, containing ubiquitin-proteasome components), and is detected in human Lewy bodies in Parkinson's disease tissue. |
In vitro binding assays (pulldown), cell-based aggresome formation assays, immunofluorescence, immunohistochemistry of human brain tissue |
Journal of molecular neuroscience |
Low |
21590270
|
| 2025 |
ARIH1 directly interacts with PHB1 via its RING1+RBR+RING2 domains and catalyzes K63-linked ubiquitination of PHB1 at K186; this modification promotes PHB1 phosphorylation by Akt and mitochondrial translocation of PHB1, maintaining mitochondrial stability and promoting oxidative phosphorylation in colorectal cancer cells. |
Co-immunoprecipitation, in vitro ubiquitination assays, site-directed mutagenesis (K186), subcellular fractionation, mitochondrial function assays |
Advanced science |
Medium |
40285603
|
| 2025 |
ARIH1 independently ubiquitinates PD-L1 in vitro (without requiring CRL as scaffold) and also cooperates with CRLs to catalyze PD-L1 ubiquitination; phosphorylation of PD-L1 enhances ubiquitination by disrupting its membrane association (demonstrated using liposomes); NEDD4 family E3s also ubiquitinate PD-L1. |
In vitro reconstitution with purified components (ARIH1, CRL3SPOP, NEDD4), liposome-based enzymatic assays, phosphorylation-mimetic mutants |
Structure |
High |
40472843
|
| 2025 |
ARIH1 mediates ubiquitination and degradation of MFN2, promoting mitophagy and endoplasmic reticulum stress in trophoblasts under hypoxia/reoxygenation conditions; ARIH1 inhibition reverses suppressed proliferation/invasion and reduces ROS, and MFN2 inhibition abolishes the protective effects of ARIH1 downregulation. |
Co-immunoprecipitation, ubiquitination assays, ARIH1 KD/overexpression, in vivo PE rat model, HTR8 cell hypoxia/reoxygenation model |
FASEB journal |
Low |
40960900
|
| 2025 |
ARIH1 interacts with NCOA4 and promotes its K48-linked ubiquitination and proteasomal degradation, thereby suppressing ferritinophagy and ferroptosis in lung adenocarcinoma; ARIH1 loss results in iron accumulation, lipid peroxidation, glutathione depletion, and ferroptotic cell death. |
Co-immunoprecipitation, ubiquitination assays (K48-linkage), cycloheximide chase, siRNA knockdown, ferroptosis marker assays |
Respiratory research |
Low |
42169065
|
| 2025 |
ARIH1 regulates learning and memory in mice by ubiquitinating and promoting degradation of GIRK2 in dorsal hippocampal CaMKII-expressing neurons; ARIH1 deficiency causes GIRK2 upregulation and spatial learning/memory deficits that are rescued by lentiviral ARIH1 restoration or GIRK channel inhibition; selective ARIH1 KD in CaMKII+ (but not PV+ or SST+) neurons recapitulates the memory deficit. |
ARIH1 heterozygous knockout mouse model, lentiviral ARIH1 rescue, cell-type-specific ARIH1 knockdown (CaMKII/PV/SST-Cre), ubiquitination assays, Morris water maze, novel object recognition, GIRK channel pharmacology |
bioRxivpreprint |
Medium |
bio_10.1101_2025.03.10.625121
|
| 2025 |
HHARI (ARIH1) stimulates IFN-β secretion by directly targeting RIG-I in a neddylation-dependent manner; the acidic N-terminal/UBA-like domains of HHARI are essential for this pro-interferon activity and for interaction with neddylated cullins; truncated HHARI containing only the N-terminal domains retains neddylation-dependent interferon signaling; overexpression of cullins 1–5 enhances HHARI-mediated IFN-β secretion. |
HHARI truncation mutants, neddylation inhibitor experiments, overexpression of cullins, IFN-β secretion assays, RIG-I interaction studies |
bioRxivpreprint |
Low |
bio_10.1101_2025.02.01.636034
|
| 2025 |
ARIH1 loss leads to MAP4 upregulation and microtubule stabilization (increased tubulin acetylation and enhanced spindle organization) in breast cancer cells, sensitizing them to paclitaxel; this identifies ARIH1 as a regulator of microtubule dynamics. |
ARIH1 siRNA knockdown in breast cancer cell lines, tubulin acetylation assays, MAP4 protein level measurement, paclitaxel sensitivity assays (viability, colony formation, apoptosis) |
Cancers |
Low |
40075632
|
| 2025 |
Pyrotinib enhances interaction between ARIH1 and HER2, promoting HER2 ubiquitination and endocytosis leading to lysosomal degradation of HER2 in HER2-positive NSCLC; tumor growth suppression by pyrotinib in vivo is ARIH1-dependent. |
Co-immunoprecipitation, ubiquitination assays, LC-MS/MS, in vivo xenograft tumor model with ARIH1 manipulation |
Cellular oncology |
Low |
41123818
|
| 2026 |
Sec61β recruits ARIH1 and 4EHP to the mRNA 5' cap to inhibit eIF4E binding, resulting in selective translational repression of ER-targeted (ERpQC substrate) mRNAs during ER stress; Sec61β deficiency causes cytoplasmic aggresome formation due to overproduction of ERpQC substrates, and motor dysfunction in zebrafish that is rescued by exogenous ARIH1 expression. |
Co-immunoprecipitation (Sec61β–ARIH1–4EHP complex), mRNA cap-binding assays, Sec61β KD, zebrafish motor behavior rescue by ARIH1 overexpression, proteasome activity assays |
EMBO reports |
Medium |
41593190
|